A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Incyte Corporation
Incyte Corporation
University of Florida
Xencor, Inc.
Incyte Corporation
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Novartis
Stanford University
University of Chicago